Compugen Ltd. (NASDAQ:CGEN) saw strong trading volume on Friday . 183,044 shares traded hands during trading, an increase of 63% from the previous session’s volume of 112,035 shares.The stock last traded at $7.02 and had previously closed at $6.92.

Several equities analysts have recently commented on the company. FBR & Co restated a “buy” rating on shares of Compugen in a research note on Thursday, May 12th. Zacks Investment Research lowered Compugen from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $10.25.

The company’s market cap is $355.85 million. The firm’s 50 day moving average price is $6.70 and its 200 day moving average price is $6.24.

Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.04. On average, analysts expect that Compugen Ltd. will post ($0.56) EPS for the current year.

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.